

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4744422

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NATIONAL RESEARCH COUNCIL OF CANADA	09/26/2013
RECEIVING PARTY DATA	
Name:	ALETHIA BIOTHERAPEUTICS INC.
Street Address:	141, PRESIDENT-KENNEDY AVE.
Internal Address:	SUITE SB-5100
City:	MONTREAL
State/Country:	CANADA
Postal Code:	H2X 1Y4
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15811545
CORRESPONDENCE DATA	
Fax Number:	(617)526-9899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 526-9706
Email:	shynes@proskauer.com
Correspondent Name:	PROSKAUER ROSE LLP
Address Line 1:	ONE INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	11504-231C1
NAME OF SUBMITTER:	JULIO J. MENDEZ
SIGNATURE:	/Julio J. Mendez/
DATE SIGNED:	12/19/2017
Total Attachments: 2	
source=11504-231C1 AssignmentNRC#page1.tif	
source=11504-231C1 AssignmentNRC#page2.tif	

Before Issue of Patent**ASSIGNMENT**

For good and valuable consideration, we (hereinafter referred to as "Assignors"):

FULL NAME OF ASSIGNOR	BUSINESS ADDRESS
NATIONAL RESEARCH COUNCIL OF CANADA	1200 Montreal Road, Ottawa, Ontario K1A 0R6, CANADA

hereby assign, vest and transfer (and/or confirm such assignment, vesting or transfer) to:

FULL NAME OF ASSIGNEE	BUSINESS ADDRESS
ALETHIA BIOTHERAPEUTICS INC.	141, Avenue President-Kennedy, Suite SB-5100, Montreal, Quebec H2X 1Y4

and its successors, assigns or legal representatives (collectively herein called the "Assignee"), the entire and exclusive right, title and interest in Canada, the United States and everywhere else throughout the world in the invention(s) and improvements which are the subject of the patent application(s) identified as:

TITLE OF APPLICATION	FILING DATE	SERIAL NUMBER
ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	March 28, 2012	PCT/CA2012/000296


and related application(s) and patent(s), this assignment including said application(s), and all United States and foreign patents granted for any of said invention(s) or improvement(s), including all divisions, continuations, renewals, reissues, reexaminations, continuations-in-part and extensions thereof, including the right to sue for damages occurring before the assignment, with all the rights, powers, privileges and advantages in anywise arising from or appertaining thereto, and the right to claim priority based on the filing date of said application(s) and based on the filing date of any provisional application of which said application(s) claims the benefit under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents and like rights of exclusion and for inventor's certificates for said inventions and improvements; and we agree for ourselves and our heirs, legal representatives and assigns, without further compensation, upon request to perform such lawful acts, to promptly provide Assignee with all pertinent facts and documents relating to said invention(s) or application(s) as may be known and accessible to us, to testify in any interference, opposition, litigation, or similar proceedings related to said invention(s) or application(s), to sign such further applications, assignments, declarations, affidavits, preliminary statements and other lawful documents as the Assignee may reasonably request to effectuate fully this


Assignment and to execute any other papers that may be needed in connection with filing said application(s) and securing Letters Patents thereon.

The Assignors hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

The Assignors hereby authorize the insertion on this Assignment of the serial number(s) and filing date(s) of said application(s) when known.

The Assignors hereby authorize the Commissioner of Patents and Trademarks, or any official whose duty it is to issue patents, to issue a Letters Patent on said application(s), and on any and all divisions, continuations, renewals, reissues, reexaminations, continuations-in-part and extensions thereof to Assignee in accordance herewith. It is the express wish of the parties that this Assignment be drafted in the English language. C'est la volonté expresse des parties que cette cession soit rédigée en langue anglaise.

SIGNED this <u>26</u> day of <u>September</u> 2013		
(day)	(month)	(year)
WITNESS:	ASSIGNOR: NATIONAL RESEARCH COUNCIL OF CANADA	
<u>Suzanne Nicholas</u>		
Full Name of Witness:	By: John R. McDougall, P.Eng	
	Title: President	

SIGNED this <u>9th</u> day of <u>December</u> 2013		
(day)	(month)	(year)
WITNESS:	ASSIGNEE: ALETHIA BIOTHERAPEUTICS INC.	
<u>Paula KHOURY</u>		
Full Name of Witness:	By: Yves Colwell	
	Title: President & CEO	